Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
13.99B
Market cap13.99B
Price-Earnings ratio
18.41
Price-Earnings ratio18.41
Dividend yield
Dividend yield
Average volume
2.47M
Average volume2.47M
High today
$56.75
High today$56.75
Low today
$55.29
Low today$55.29
Open price
$55.57
Open price$55.57
Volume
2.01M
Volume2.01M
52 Week high
$57.57
52 Week high$57.57
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

Exelixis(EXEL) stock is priced at $55.68, giving the company a market capitalization of 13.99B. It carries a P/E multiple of 18.41.

On 2026-07-16, Exelixis(EXEL) stock moved within a range of $55.29 to $56.75. With shares now at $55.68, the stock is trading +0.7% above its intraday low and -1.9% below the session's peak.

Trading activity shows a volume of 2.01M, compared to an average daily volume of 2.47M.

The stock's 52-week range extends from a low of $33.76 to a high of $57.57.

The stock's 52-week range extends from a low of $33.76 to a high of $57.57.

EXEL News

Simply Wall St 2d
Exelixis Stock May Be Undervalued Following FDA Review Uncertainty

Exelixis stock has already delivered a very strong 243.8% return over the past 5 years, yet valuation checks still flag it as looking cheap on several measures,...

Exelixis Stock May Be Undervalued Following FDA Review Uncertainty
TipRanks 2d
Exelixis price target raised to $49 from $45 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $49 from $45 and keeps an Equal Weight rating on the shares. The firm adjuste...

Analyst ratings

52%

of 21 ratings
Buy
38.1%
Hold
52.4%
Sell
9.5%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.